Silvernail Named CFO of Evolus

Evolus Prepares for Botulinum Toxin Launch

Lauren Silvernail, former chief financial officer (CFO) and chief business officer at Revance Therapeutics, is now the CFO and executive vice president of corporate development at Evolus. Prior to her time at Revance, Silvernail served as CFO and VP of corporate development at ISTA Pharmaceuticals. She joins the company as it works towards approval of its prabotulinumtoxinA injectable (DWP-450) for the treatment of moderate-to-severe glabellar lines.

“I welcome Lauren to Evolus as her appointment further strengthens our executive leadership team and represents a critical milestone for the company ahead of commercialization,” said David Moatazedi, president and CEO of Evolus. “Lauren brings extensive category experience and deep financial, operational, commercial and corporate development expertise as we prepare to bring our first product candidate to market.”

Image: Lauren Silvernail